These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27160286)

  • 41. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
    Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
    Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
    Ando M; Hasegawa Y; Ando Y
    Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
    Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
    J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
    Dias MM; McKinnon RA; Sorich MJ
    Pharmacogenomics; 2012 Jun; 13(8):889-99. PubMed ID: 22676194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.
    Hirasawa A; Zama T; Akahane T; Nomura H; Kataoka F; Saito K; Okubo K; Tominaga E; Makita K; Susumu N; Kosaki K; Tanigawara Y; Aoki D
    J Hum Genet; 2013 Dec; 58(12):794-8. PubMed ID: 24088669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
    de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
    Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
    Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
    Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).
    Med Lett Drugs Ther; 2006 May; 48(1234):39-40. PubMed ID: 16685247
    [No Abstract]   [Full Text] [Related]  

  • 51. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
    Ishikawa K; Kajita Y; Hasegawa Y; Noda Y; Yoshida J; Nabeshima T
    J Neurooncol; 2005 Sep; 74(3):283-6. PubMed ID: 16187025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
    Ma L; Chen Y; Yang C; Jiang H; Zhu J; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):29-32. PubMed ID: 25877315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
    Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
    Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
    Hirata K; Nagata N; Kato T; Okuyama Y; Andoh H; Takahashi K; Oba K; Sakamoto J; Hazama S; Mishima H
    Anticancer Res; 2014 Jan; 34(1):195-201. PubMed ID: 24403462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.
    Tsunedomi R; Hazama S; Okayama N; Oka M; Nagano H
    Cancer Sci; 2017 Jul; 108(7):1504-1509. PubMed ID: 28474802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
    Wang Y; Xu JM; Shen L; Xu N; Wang JW; Jiao SC; Zhang JS; Song ST; Li J; Bao HY; Yang L; Li F
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):913-6. PubMed ID: 18478930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
    Hoskins JM; Goldberg RM; Qu P; Ibrahim JG; McLeod HL
    J Natl Cancer Inst; 2007 Sep; 99(17):1290-5. PubMed ID: 17728214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
    Ichikawa W; Uehara K; Minamimura K; Tanaka C; Takii Y; Miyauchi H; Sadahiro S; Fujita K; Moriwaki T; Nakamura M; Takahashi T; Tsuji A; Shinozaki K; Morita S; Ando Y; Okutani Y; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
    Br J Cancer; 2015 May; 112(10):1709-16. PubMed ID: 25880011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.